Unveiling a New Era in PEG Detection: PEG (Backbone-Specific) Rabbit Monoclonal Antibody Makes the "Invisible" Polymer Detectable

In the intricate world of biomedicine, polyethylene glycol (PEG) functions like a "molecular magician"—serving as an "invisibility cloak" to prolong drug half-life and a "gold-standard adjuvant" for vaccines. This polymer, composed of repeating [-CH₂-CH₂-O-] units, is reshaping the future of medicine with an annual market growth rate of 15%.

What is PEG?

Polyethylene glycol (PEG) is a polymer consisting of repeating ethylene glycol units [-CH₂-CH₂-O-].

Notable Properties:

Exceptional Biocompatibility: PEG is non-toxic, non-immunogenic, and highly compatible with biological tissues, making it ideal for biomedical applications.

Excellent Water Solubility: PEG readily dissolves in aqueous systems, simplifying experimental procedures.

Customizable Molecular Weight and Structure: PEG is available in a wide range of molecular weights, with linear or branched architectures, and can be chemically modified to meet diverse application needs.

Thanks to these characteristics, PEGylation has become an FDA-approved strategy for protein drug delivery, offering the following advantages:

Improved Pharmacokinetics and Pharmacodynamics: Studies show that PEGylation significantly alters in vivo pharmacokinetic properties, including prolonged plasma half-life, enhanced drug release, and reduced renal clearance.

Enhanced Drug Stability: PEGylation forms a dense hydration layer on proteins and peptides, preventing aggregation and precipitation. PEG-lipid conjugates (linked via acyl, ether, or disulfide bonds) can also improve liposome stability. Additionally, PEG’s flexible chains create steric hindrance, protecting conjugated molecules from protease degradation.

Optimized Biodistribution: PEGylation increases molecular weight, reducing renal filtration and urinary excretion. It also enhances systemic circulation stability and retention time, promoting drug accumulation in target tissues (e.g., tumors and inflamed sites) via the enhanced permeability and retention (EPR) effect.

FDA-Approved PEGylated Therapeutics

Accurate and sensitive quantification of PEG conjugates is critical for drug development and research.

Hangzhou Starter Bio introduces the high-affinity PEG antibody—PEG (Backbone-Specific) Recombinant Rabbit mAb (S-1832-13) (Catalog No.: S0B1442)—enabling efficient anti-drug antibody (ADA) and pharmacokinetic (PK) analysis of PEGylated therapeutics. This antibody offers the following advantages:

Proprietary Rabbit Monoclonal B-Cell Platform: Ensures high-quality antibody production.

High Affinity: Enables sensitive and specific PEG detection.

Minimal Cross-Reactivity: Eliminates interference from structurally similar molecules, ensuring assay accuracy.

Western Blot (WB) Compatibility: Optimized for reliable and reproducible WB results.

Rigorous Quality Control: Guarantees batch-to-batch consistency and stability.

Expert Technical Support: Our experienced team provides comprehensive solutions for your research needs.

Applications:Drug Delivery Assessment: Tracks in vivo distribution and metabolism of PEGylated drugs to evaluate delivery efficacy.

Reliable Experimental Outcomes: High specificity minimizes false positives, ensuring data reliability.

Validation Data: 

WB result of PEG (backbone specific) Recombinant Rabbit mAb
Primary antibody: PEG (backbone specific) Recombinant Rabbit mAb at 1/1000 dilution
Lane 1: BSA-PEG 2K (Hydroxyl terminal) 1 µg
Lane 2: BSA-PEG 5K (carboxyl terminal) 1 µg
Lane 3: BSA-PEG 20K (methoxy terminal) 1 µg
Secondary antibody: Goat Anti-rabbit IgG, (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 70-200 kDa
Observed MW: 70-200 kDa
This blot was developed with high sensitivity substrate

Click on the product catalog numbers below to access detailed information on our official website.

Product Information